Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Diabetes, Obesity and Metabolism |
| Vol/bind | 25 |
| Udgave nummer | 10 |
| Sider (fra-til) | 3064-3067 |
| Antal sider | 4 |
| ISSN | 1462-8902 |
| DOI | |
| Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
The authors thank all participants and clinical trial staff for participation in this study. The study was funded by Boehringer Ingelheim and a grant from the Novo Nordisk Foundation (NNF14OC0013659 PROTON Personalizing Treatment of Diabetic Nephropathy). The funders were not involved in the design, execution, analysis, interpretation of the data nor in the writing of the manuscript.
ID: 365814070